echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Academician Liu Changxiao: innovation, challenge, generic medicine and traditional Chinese medicine are the four focuses of the industry in the next 10 years

    Academician Liu Changxiao: innovation, challenge, generic medicine and traditional Chinese medicine are the four focuses of the industry in the next 10 years

    • Last Update: 2019-12-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 28, under the guidance of China Pharmaceutical Materials Association, the "2019 China Pharmaceutical new wisdom forum" jointly sponsored by Sina pharmaceutical and China Pharmaceutical Materials Association think tank for food and drug industry was held in Beijing The theme of this conference is "gather wisdom and generate wisdom in a big wave" Industry experts and enterprise representatives gather to find out the variables and future of China's pharmaceutical industry and talk about the next golden decade of industrial development! At the meeting, Liu Changxiao, academician of the Chinese Academy of engineering, delivered a keynote speech on "future development forecast: insight into the next 10 years of biomedicine", which predicted four focuses in the field of biomedicine in China in the next 10 years, namely innovation, challenge, generic medicine and traditional Chinese medicine It is proposed that "intelligent manufacturing, green manufacturing" is the fundamental development of China's biomedical industry in the new era, and innovation is the core throughout the progress of pharmaceutical R & D industry The following is the actual record of Liu Changxiao's speech (some of which are deleted): Since the founding of the people's Republic of China 70 years ago, the ability of new drug creation in China has emerged: the level of pre clinical research and evaluation of new drugs has been improved in line with the international standard, the national drug innovation technology body has been initially established, the talent team and management level have been continuously improved, the research and development achievements of modernization and internationalization of major varieties innovation research and development have been remarkable, and the national survey of traditional Chinese medicine resources has provided a branch for mastering the development and utilization of resources in China According to the research, we should promote the steady development of the pharmaceutical industry in the new drug creation project, and reform the supply side After the reform and opening up, China's pharmaceutical industry has shown three poles of development: foreign capital, state-owned capital and private capital However, there is still a long way to go to solve the problem of "lack of medical care and medicine" for the people First, foreign pharmaceutical enterprises have entered the market in a large scale: China has become the forefront of the global pharmaceutical market Second, the development of state-owned pharmaceutical enterprises is unbalanced: in this stage, the "eldest sons" of the pharmaceutical industry in the North China, Xinhua, northeast, northwest and other republics of the "old four" are developing slowly, and the overall development potential of the pharmaceutical and people's livelihood state-owned industry is insufficient Third, the emergence of private pharmaceutical enterprises: there is a multi-level development pattern of state-owned capital to private capital transfer, but the "new four" is taking shape According to statistics of major death factors in China from 1990 to 2017, cancer accounted for 4 of the 10 major diseases (lung cancer, liver cancer, gastric cancer, esophageal cancer) Because cancer incidence rate is increasing and people's demand is bigger, anticancer drugs are new research hotspots However, the development of medicine and pharmacy is not an overnight process, but a process of accumulation, otherwise it can only be a flash in the pan, and there is no way to have a good effect on clinical needs Generally speaking, in the third year after the drug goes on the market, there will be a lot of generic drugs coming out, the price may be one third or even one tenth of the price of the drug just on the market, so many large enterprises will no longer appear in the market with the original research drugs, and the quality of the new generic drugs is not inferior to the original research to some extent A few years ago, we were discussing how to make clinical new drugs grow rapidly and succeed? There are many varieties of clinical drugs, but few of them have been registered and successfully marketed After being approved, more than half of them may not have good economic benefits Some drugs are eliminated due to the problem of clinical efficacy And then there is the problem of high R & D cost Last year, we counted several large pharmaceutical companies The costs of publicity, training, commercial consumption, etc are far greater than the economic R & D cost How to treat these high cost problems? The newly developed drugs are not necessarily very mature Innovation requires money, patience and scientific evaluation and analysis These historical lessons must be taken into account in drug development Due to the high cost of different drugs, the return on innovation is lower year by year, so some aspects may also affect the enthusiasm of enterprise innovation From the perspective of innovation and money burning: new drug R & D is a commercial science, including the competitiveness of commercial science, the success or failure of business, and the risk of business value These are also the rules of new drugs, basically in line with the business model Brand value is the basis of enterprise development, and the balanced structure of biomedicine is the basis of ensuring people's livelihood needs At present, there are more over-the-counter drugs in China than in other countries, and the prescription drugs are basically the same How to play the leading role of drugstores? It is imperative to realize the system construction of medical diagnosis, medical insurance payment and online sale In the future, the U.S will still be the largest drug market, but China's share is gradually increasing, but there is still a big gap from the U.S The contribution rate of innovation is the same China is still relatively low, and now it is entering the second tier However, compared with Switzerland, France and Germany, there is still a big gap Biopharmaceutics is one of the ten key areas of manufacturing 4.0 in China, which is the direction that should be made in the next decade "Intelligent manufacturing, green manufacturing" is the fundamental development of Chinese Biopharmaceutics in the new era General secretary Xi Jinping said that the Chinese people should put the bottles of medicine in their own hands and install their own medicines, so that they can not become a foreign drug colony step by step We should have a kind of self-improvement thought and idea to be our medicine, that is, social responsibility, sense of responsibility and our mission Many enterprises are very pompous and eager for success The United States loses 28 billion scientific research achievements every year, so any innovation is very important In the future, the four modes of innovation we expect determine the development of biomedicine, and we hope Sina can make some contributions We should have a business model to deal with industrial demand Franck believes that innovation is the need of the market and the positive energy for our development in the future, because China is a country with a large population and capital In the next ten years, China's approval of innovative drugs will surpass that of the United States Many foreign enterprises need to integrate their development with China's needs, and the introduction of approved products should be guided by clinical needs What is the future trend forecast? Prediction 1: innovation More openness promotes the development of pharmaceutical globalization; capital technology market promotes reorganization and merger; smart manufacturing will make breakthroughs; new drug law and Chinese pharmaceutical demand promote and speed up the application, review and listing of original new drugs in China
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.